The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
A pilot study of supraphysiologic testosterone (T) and oral etoposide (E) in men with castrate-resistant prostate cancer (CRPC).
Michael Thomas Schweizer
No relevant relationships to disclose
Emmanuel S. Antonarakis
No relevant relationships to disclose
Hao Wang
No relevant relationships to disclose
Avery N. Spitz
No relevant relationships to disclose
Haiyi Cao
No relevant relationships to disclose
Alberto Pacheco
No relevant relationships to disclose
Mario A. Eisenberger
No relevant relationships to disclose
Michael Anthony Carducci
No relevant relationships to disclose
Samuel R. Denmeade
No relevant relationships to disclose